

Danielle M Brander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6979861/publications.pdf>

Version: 2024-02-01

69
papers

2,421
citations

430874

18
h-index

206112

48
g-index

69
all docs

69
docs citations

69
times ranked

2232
citing authors

#	ARTICLE	IF	CITATIONS
1	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. <i>Leukemia</i> , 2022, 36, 119-125.	7.2	10
2	Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. <i>European Journal of Haematology</i> , 2022, , .	2.2	0
3	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K γ inhibitor therapy. <i>Blood</i> , 2021, 137, 2817-2826.	1.4	38
4	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. <i>Blood</i> , 2021, 137, 2046-2056.	1.4	16
5	Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. <i>Blood</i> , 2021, 138, 836-846.	1.4	27
6	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021, 35, 2854-2861.	7.2	12
7	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. <i>Haematologica</i> , 2021, 106, 2845-2852.	3.5	18
8	Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax. <i>Blood</i> , 2021, 138, 2628-2628.	1.4	10
9	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. <i>Blood</i> , 2021, 138, 2637-2637.	1.4	1
10	Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study. <i>Blood</i> , 2021, 138, 392-392.	1.4	15
11	Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 640-640.	1.4	4
12	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021, 138, 639-639.	1.4	27
13	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG) Tj ETQq1 1 ⁴ 0.784314 rgBT /O	1.4	14
14	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 918-923.	2.5	19
15	A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy. <i>Medical Mycology Case Reports</i> , 2020, 27, 17-21.	1.3	10
16	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	5.2	55
17	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	7.0	80
18	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2020, 106, 284-287.	3.5	8

#	ARTICLE	IF	CITATIONS
19	A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 21-22.	1.4	8
20	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
21	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2
22	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e419-e428.	4.6	60
23	Post-translational regulation could be determine functional differences between SET alpha and beta isoform " Response to Crizotinib. <i>British Journal of Haematology</i> , 2019, 186, 637-637.	2.5	0
24	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	7.0	61
25	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	5.2	26
26	SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 605-615.	2.5	24
27	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	1.4	4
28	High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR). <i>Blood</i> , 2019, 134, 4291-4291.	1.4	1
29	Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. <i>Blood</i> , 2019, 134, 1756-1756.	1.4	1
30	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT). <i>Blood</i> , 2019, 134, 4286-4286.	1.4	3
31	A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas. <i>Blood</i> , 2019, 134, 810-810.	1.4	9
32	Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL. <i>Blood</i> , 2019, 134, 3036-3036.	1.4	9
33	Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents. <i>Blood</i> , 2019, 134, 3321-3321.	1.4	2
34	Curriculum in Chronic Lymphocytic Leukemia Narrows the Educational Gaps of the Oncology Healthcare Team. <i>Blood</i> , 2019, 134, 5878-5878.	1.4	0
35	Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis. <i>Blood</i> , 2019, 134, 4004-4004.	1.4	0
36	Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. <i>Blood</i> , 2019, 134, 3048-3048.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Umbralisib, a novel PI3K γ and casein kinase-1 μ inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. <i>Lancet Oncology</i> , The, 2018, 19, 486-496.	10.7	178
38	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , 2018, 103, 874-879.	3.5	329
39	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528.	27.0	706
40	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	3.5	135
41	Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab. <i>Blood</i> , 2018, 132, 183-183.	1.4	5
42	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. <i>Blood</i> , 2018, 132, 3142-3142.	1.4	2
43	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. <i>Blood</i> , 2018, 132, 6-6.	1.4	18
44	Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation. <i>Blood</i> , 2018, 132, 297-297.	1.4	14
45	Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings. <i>Blood</i> , 2018, 132, 4410-4410.	1.4	0
46	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. <i>Blood</i> , 2018, 132, 4414-4414.	1.4	1
47	Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration. <i>Blood</i> , 2018, 132, 1648-1648.	1.4	0
48	Exercise and Chronic Lymphocytic Leukemia (CLL) - Relationships Among Physical Activity, Fitness, & Inflammation, and Their Impacts on CLL Patients. <i>Blood</i> , 2018, 132, 5540-5540.	1.4	1
49	Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. <i>Blood</i> , 2018, 132, 4759-4759.	1.4	1
50	Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. <i>Lancet Oncology</i> , The, 2017, 18, 230-240.	10.7	287
51	Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B κ cell receptor pathway and anti κ apoptotic inhibitors: how do we mix, match, and move forward?. <i>British Journal of Haematology</i> , 2017, 176, 337-340.	2.5	0
52	Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. <i>Lancet Haematology</i> , the, 2016, 3, e407-e414.	4.6	16
53	Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 2033-2033.	1.4	6
54	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. <i>Blood</i> , 2016, 128, 3222-3222.	1.4	16

#	ARTICLE	IF	CITATIONS
55	Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. <i>Blood</i> , 2016, 128, 3243-3243.	1.4	15
56	Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. <i>Blood</i> , 2016, 128, 4400-4400.	1.4	2
57	TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 4154-4154.	1.4	20
58	Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study. <i>Blood</i> , 2015, 126, 830-830.	1.4	38
59	TGR-1202, a Novel Once Daily PI3K δ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 1984-1984.	1.4	14
60	Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 325-325.	1.4	32
61	Final Clinical Results with Laboratory Correlates in the Phase I Trial of Lenalidomide Plus Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 5658-5658.	1.4	2
62	Activity of TGR-1202, a novel once-daily PI3K δ inhibitor, in patients with relapsed or refractory hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2513-2513.	1.6	10
63	Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2627-2630.	1.3	5
64	Laboratory Correlates and a Phase I Clinical Trial Of Lenalidomide In Combination With Plerixafor In Patients With Previously Treated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 5301-5301.	1.4	0
65	Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib. Patient Preference and Adherence, 2012, 6, 239.	1.8	2
66	Comparison of the PI3K- δ Inhibitors TGR1202 and GS-1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in CLL Cells in Vitro. <i>Blood</i> , 2012, 120, 3914-3914.	1.4	5
67	Circulating B Cell Clones in Familial Waldenström Macroglobulinemia.. <i>Blood</i> , 2012, 120, 2703-2703.	1.4	0
68	Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1626-1626.	1.4	0
69	The Role of Surface Immunoglobulin Isotype in Chronic Lymphocytic Leukemia Disease Biology and Clinical Outcome. <i>Blood</i> , 2011, 118, 2850-2850.	1.4	0